Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 11

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 11
---
,964 

   The warrant liability was determined based on the fair value of 2023 Common Warrants at the issue date and the reporting dates using the Black-Scholes model with the following weighted-average assumptions will expire on the earlier of (i) the 60th day after the date of the acceptance by the FDA of an NDA for the Company's product candidate GTx-104 and (ii) five years from the date on issuance.              June 30, 2025      March 31, 2025      Risk-free interest rate   4.22%   4.18%    Share price  $2.97   $2.28     Expected warrant life   0.90    1.14     Dividend yield   0%   0%    Expected volatility   66.72%   74.26% 
  The weighted average fair values of the 2023 Common Warrants were determined to be $0.64 and $0.45 per 2023 Common Warrant as of June 30, 2025, and March 31, 2025, respectively. The risk-free interest rate at the issue date and on the reporting date of June 30, 2025 was based on the interest rate corresponding to the U.S. Treasury rate issue with a remaining term equal to the expected term of the 2023 Common Warrants. The expected volatility was based on the historical volatility for the Company.  As of June 30, 2025 and March 31, 2025, the balance of derivative warrant liabilities from related parties was $1,357 and $952, respectively.

   7. Stock-based compensation

   2024 Equity Incentive Plan

   At the Annual and Special Meeting of Shareholders on September 30, 2024, the Company’s shareholders approved the Acasti Pharma Inc. 2024 Equity Incentive Plan (the “2024 Plan”) which became effective on the date of the Domestication. The 2024 Plan replaced the Acasti Pharma Inc. Stock Option Plan and the Acasti Pharma Inc. Equity Incentive Plan (the “Prior Plans”). The 2024 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, performance-based awards and other equity-based awards to eligible persons as defined